In Vitro Activity of Cefixime and Six Other Agents Against Nosocomial Pathogens of the Enterobacteriaceae Family
- 1 June 1987
- journal article
- research article
- Published by Cambridge University Press (CUP) in Infection Control
- Vol. 8 (6) , 241-244
- https://doi.org/10.1017/s019594170006611x
Abstract
Cefixime, a broad-spectrum, orally active cephalosporin, was more active in vitro than ampicillin, cefaclor, cephalothin, and trimethoprim/sulfamethoxazole against 194 nosocomial pathogens of the family Enterobacteriaceae. Activity was especially good against Klebsiella spp, Proteus spp, Serratia spp, and Providencia stuartii. Although gentamicin had equivalent or better activity against Citrobacter spp, Enterobacter spp, Escherichia coli, and Morganella morganii, all 23 of the gentamicin-resistant strains studied were susceptible to Cefixime. Isolates tested were from urinary tract infections, abdominal infections, wounds, vascular infections, and respiratory infections; they were sequentially collected nosocomial pathogens from a single institution. This orally active cephalosporin should be considered for therapy of a variety of nosocomial infections involving gram-negative bacillary pathogens.This publication has 4 references indexed in Scilit:
- In vitro evaluation of cefixime (FK027, FR17027, CL284635): Spectrum against recent clinical isolates, comparative antimicrobial activity, β-lactamase stability, and preliminary susceptibility testing criteriaDiagnostic Microbiology and Infectious Disease, 1986
- The pharmacokinetic and bactericidal characteristics of oral cefiximeClinical Pharmacology & Therapeutics, 1985
- Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporinAntimicrobial Agents and Chemotherapy, 1984
- In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibioticAntimicrobial Agents and Chemotherapy, 1984